Kezdőlap・Részvénylista・IQVIA Holdings Inc

IQVIA Holdings Inc

Lezárt

SzektorEgészségügy

237.15 -0.89

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

237.02

Maximum

243.97

Fő mutatók
By Trading Economics
Bevétel	-17M 258M
Értékesítés	217M 4.4B
P/E Szektor átlag	30.137 57.002
Egy részvényre jutó nyereség	2.75
Profit margin	5.907
Munkavállalók	94,000
EBITDA	-18M 790M

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+13.12% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. okt. 27.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	4.2B 40B
Előző nyitás	238.04
Előző zárás	237.15

Hangulat hírek alapján

By Acuity

50%

152 / 340 Rangsor szerint Healthcare

IQVIA Holdings Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 12. 19:46 UTC

News

IQVIA Holdings reported $3.2 billion in new bookings for Q2 2026, but shares are trading lower despite strong growth metrics.

2026. aug. 11. 22:46 UTC

IQVIA Holdings Inc shares are trading higher in after-market hours, showing strength despite a broader market decline influenced by rising crude oil prices.

2026. aug. 10. 23:01 UTC

IQVIA Holdings Inc is trading higher in after-market hours, maintaining a steady upward trajectory and positioning above its 20-day moving average.

2026. aug. 8. 00:01 UTC

IQVIA Holdings Inc shares are lower in after-market hours amid broader market concerns over Federal Reserve interest rate policies and a recent weak jobs report.

2026. aug. 7. 23:01 UTC

IQVIA Holdings Inc shares are lower in after-market hours, continuing a decline since Friday's close with no specific news identified for the drop.

2026. aug. 6. 20:06 UTC

IQVIA Holdings Inc shares are declining today, breaking a trend of higher closes since Wednesday. No specific news was identified to explain this movement.

2026. aug. 5. 20:03 UTC

Correlated Moves

News

IQVIA Holdings announced a collaboration with Medera to advance cardiac gene therapies. Positive sentiment from this partnership likely supported shares trading higher today.

2026. aug. 4. 23:01 UTC

News

IQVIA Holdings Inc announced a collaboration with Medera to enhance cardiac gene therapies. Shares declined during after-market trading, continuing a trend of lower closes.

2026. aug. 3. 20:06 UTC

IQVIA Holdings Inc. shares are lower today, breaking a trend of higher closes since Friday. No specific company news was identified to explain the move.

2026. júl. 31. 19:16 UTC

News

Shares of IQVIA Holdings lower after first-quarter results.

2026. júl. 30. 23:02 UTC

IQVIA Holdings Inc shares are higher in after-market trading, reflecting positive momentum since Thursday's close, despite no specific news driving the movement.

2026. júl. 29. 22:06 UTC

Correlated Moves

IQVIA Holdings shares declined in after-hours trading, reflecting broader market unease following the Federal Reserve's decision to maintain interest rates.

2026. júl. 28. 20:51 UTC

IQVIA Holdings Inc is trading lower in after-market hours, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

2026. júl. 27. 23:12 UTC

IQVIA Holdings Inc. shares are higher in after-market trading, tracking broader gains in European markets, including a rise in the DAX 30 Index.

2026. júl. 23. 20:03 UTC

Correlated Moves

IQVIA Holdings Inc shares are higher, supported by a rise in Thermo Fisher Scientific Inc's stock and positive sentiment in the life sciences sector.

2026. júl. 22. 16:36 UTC

IQVIA Holdings Inc shares are lower today, continuing a trend of declines. Broader market sentiment is affected by rising crude oil prices and geopolitical tensions.

2026. júl. 21. 19:06 UTC

Social Media

Shares of IQVIA Holdings Inc are lower following disappointing first-quarter results. Unusual call options activity exceeding $2 million indicates heightened investor interest.

Társak összehasonlítása

Árváltozás

IQVIA Holdings Inc Előrejelzés

Célár

By TipRanks

13.12% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 273.43 USD 13.12%

Magas 300 USD

Alacsony 240 USD

16 Wall Street elemző 12 hónapos célárain alapulva a(z)IQVIA Holdings Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

16 ratings

Vétel

Tartás

Eladás

16 Wall Street elemző célárain alapulva a(z)IQVIA Holdings Inc termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

152 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.